Clariant combines improving 18% margins, specialty-chemical moat and a CHF 20.67 probability-weighted five-year value against CHF 10.45, despite muted near-term growth and cyclical risks.
Overview
Clariant is a Muttenz-headquartered specialty chemical company operating in more than 50 countries, with a streamlined portfolio centered on Care Chemicals, Catalysts, and Adsorbents & Additives after divesting Masterbatches, Pigments and its Scientific Design stake. The model increasingly emphasizes specification-driven, high-margin chemistry rather than commodity volume. Care Chemicals generated FY2025 revenue of CHF 2,112 million, Catalysts CHF 816 million and Adsorbents & Additives CHF 987 million. **Operational execution is improving:** EBITDA b.e.i. margin reached 17.8% in FY2025 and 18.2% in Q2 2026, while LTM FCF conversion rose to 52%. Q2 sales of CHF 941.3 million were up 0.6% in comparable local currency, despite a 13.3% Catalysts decline caused by Middle East disruption. FY2026 guidance remains approximately flat local-currency sales versus CHF 3,915 million and an approximately 18.0% margin, with CHF 100 million of savings targeted by 2027. At CHF 10.45, the stock trades near 7.1–7.3x FY2026e EV/EBITDA and approximately 12.3x forward P/E, versus 11.0–16.0x for selected specialty peers, while offering roughly a 4% yield. Near-term catalysts include Catalyst normalization, CHF 230 million Stahl proceeds, savings delivery and the removal of the Shell litigation overhang.